What is Enliven Therapeutics Earnings Power Value (EPV)?
As of Mar24, Enliven Therapeutics's earnings power value is $7.62. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Enliven Therapeutics Earnings Power Value (EPV) Historical Data
The historical data trend for Enliven Therapeutics's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics Earnings Power Value (EPV) Chart
|
Enliven Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Earnings Power Value (EPV) |
|
- |
- |
- |
- |
|
Enliven Therapeutics Quarterly Data
|
|
Dec20 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Enliven Therapeutics's Earnings Power Value (EPV)
For the Biotechnology subindustry, Enliven Therapeutics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Earnings Power Value (EPV) falls into.
Enliven Therapeutics Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Enliven Therapeutics (Enliven Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
| Anish Patel |
officer: Chief Operating Officer |
C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Benjamin Hohl |
officer: Chief Financial Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Joseph P Lyssikatos |
director, officer: Chief Scientific Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Samuel Kintz |
director, officer: President and CEO |
ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Richard A. Heyman |
director |
5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| 5am Partners Vi, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Rishi Gupta |
director, 10 percent owner |
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
| Andrew J. Schwab |
director |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Helen Louise Collins |
director |
TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
| Jake Bauer |
director |
C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| 5am Opportunities I, L.p. |
10 percent owner |
501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Opportunities I (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Orbimed Genesis Gp Llc |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Kush Parmar |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Ventures Vi, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Enliven Therapeutics (Enliven Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your